Shots:

• The companies collaborated to evaluate ADG106 + Keytruda in dose-escalation and expansion clinical study to treat advanced or metastatic solid tumors & hematological malignancies
• In preclinical studies- ADG106 showed antitumor activity and was well tolerated as a monothx. and in combination with other immuno-oncology therapies
• ADG106 is a fully human- ligand-blocking- agonistic anti-CD137 IgG4 mAb engineered using its NEObody platform technology & is being evaluated in a P-Ib/II combination study for advanced solid tumors and r/r NHL- based on the P-I data

  Ref: Globe Newswire | Image: Merck